Tamibarotene for the Treatment of Bronchiolitis Obliterans Associated With Chronic Graft-vs-Host Disease

Chest. 2019 Jan;155(1):e1-e4. doi: 10.1016/j.chest.2018.08.1052.

Abstract

Bronchiolitis obliterans (BO) is a significant life-threatening complication that occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and it is associated with increased morbidity and mortality. BO responds poorly to corticosteroids or immunosuppressants, and there are currently no established treatment approaches. We herein describe a patient with biopsy-proven BO after allo-HSCT who was successfully treated with tamibarotene, a novel synthetic retinobenzoic acid. Tamibarotene led to a dramatic improvement in lung function as well as cutaneous manifestations of chronic graft-vs-host disease. A large prospective clinical trial is therefore warranted to confirm the efficacy of tamibarotene in BO.

Keywords: bronchiolitis obliterans; graft-vs-host disease; tamibarotene.

Publication types

  • Case Reports

MeSH terms

  • Allografts
  • Benzoates / therapeutic use*
  • Biopsy
  • Bronchiolitis Obliterans / diagnosis
  • Bronchiolitis Obliterans / drug therapy*
  • Bronchiolitis Obliterans / etiology
  • Chronic Disease
  • Follow-Up Studies
  • Graft vs Host Disease / complications*
  • Graft vs Host Disease / diagnosis
  • Graft vs Host Disease / drug therapy
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Leukemia, Promyelocytic, Acute / therapy
  • Lung / diagnostic imaging
  • Male
  • Middle Aged
  • Tetrahydronaphthalenes / therapeutic use*
  • Tomography, X-Ray Computed

Substances

  • Benzoates
  • Tetrahydronaphthalenes
  • tamibarotene